1/12
08:30 am
dwtx
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Medium
Report
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
12/22
11:20 am
dwtx
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron [Yahoo! Finance]
Low
Report
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron [Yahoo! Finance]
12/22
11:00 am
dwtx
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain [Yahoo! Finance]
High
Report
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain [Yahoo! Finance]
12/22
10:15 am
dwtx
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
High
Report
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
12/13
01:10 am
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) was downgraded by analysts at
Wall St
Medium
Report
Dogwood Therapeutics (NASDAQ:DWTX) was downgraded by analysts at
Wall St
11/26
01:14 pm
dwtx
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]
Low
Report
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]
11/6
08:45 am
dwtx
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Medium
Report
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results